ADC Therapeutics (ADCT) Equity Ratio (2019 - 2023)
Historic Equity Ratio for ADC Therapeutics (ADCT) over the last 3 years, with Q3 2023 value amounting to 118.44.
- ADC Therapeutics' Equity Ratio fell 910.71% to 118.44 in Q3 2023 from the same period last year, while for Sep 2023 it was 118.44, marking a year-over-year decrease of 910.71%. This contributed to the annual value of 0.16 for FY2022, which is 9999.99% down from last year.
- Per ADC Therapeutics' latest filing, its Equity Ratio stood at 118.44 for Q3 2023, which was down 910.71% from 114.34 recorded in Q2 2023.
- In the past 5 years, ADC Therapeutics' Equity Ratio registered a high of 143.44 during Q2 2022, and its lowest value of 0.0 during Q3 2021.
- Moreover, its 3-year median value for Equity Ratio was 114.34 (2023), whereas its average is 70.37.
- Within the past 5 years, the most significant YoY rise in ADC Therapeutics' Equity Ratio was 9257629566.28% (2022), while the steepest drop was 3337.06% (2022).
- Over the past 3 years, ADC Therapeutics' Equity Ratio (Quarter) stood at 0.24 in 2021, then plummeted by 33.37% to 0.16 in 2022, then soared by 73071.67% to 118.44 in 2023.
- Its last three reported values are 118.44 in Q3 2023, 114.34 for Q2 2023, and 129.76 during Q1 2023.